We investigated the effects of HMG-CoA reductase inhibitors, so-called statins, on 5, 6, 7, ) metabolism in human umbilical vein endothelial cells (HUVEC). The mRNA of GTP cyclohydrolase I (GTPCH), as well as cNOS, was upregulated in HUVEC treated with cerivastatin. This increase was time-and dose-dependent. Fluvastatin was also observed to enhance GTPCH and eNOS mRNA levels. In parallel with this observation, cerivastatin increased intracellular BH 4 . Cerivastatin increased the stability of eNOS mRNA. However, it did not alter the stability of GTPCH mRNA but increased GTPCH gene transcription as shown by nuclear run-on assays. Preteatment of HUVEC with the selective GTPCH inhibitor, 2,4-diamino-6-hydroxypyrimidine, caused a decrease in intracellular BH 4 and decreased citrulline formation following stimulation with ionomycin. Furthermore, the potentiating effect of cerivasatin was decreased by limiting the cellular availability of BH 4 . In addition to augmenting eNOS expression, statins potentiate GTPCH gene expression and BH 4 synthesis, thereby increasing NO production and preventing relative shortages of BH 4 .
Introduction
Over the past several years, numerous additional effects of statins on vascular cells have been identified which appear to modulate atherogenesis, plaque rupture, or thrombosis. Some of these appear to operate independently of the cholesterol lowering mechanism (1, 2) . For example, statins may upregulate nitric oxide (NO) expression by interfering with posttranscriptional regulation of endothelial NO synthase (eNOS) (3, 4) . 5, 6, 7, ) is one of the most potent naturally occurring reducing agents and an essential cofactor for enzymatic NOS activity. A suboptimal concentration of BH 4 reduces NO formation and favours uncoupling of NOS, leading to NOSmediated reduction of oxygen and the formation of superoxide anions and hydrogen peroxide (5-7). Recent findings suggest that accelerated catabolism of BH 4 in arteries exposed to oxidative stress may contribute to the pathogenesis of endothelial dysfunction in arteries of hypertensive individuals, as well as those suffering from hypercholesterolemia, diabetes, smoking, or ischcmia-rcpcrfusion injury. Beneficial cffccts of acute and chronic BH 4 supplementation on endothelial function have been reported in animals and humans (8) (9) (10) (11) (12) . In the present study, we have examined the effect of statins on GTPCH mRNA and intracellular biopterin in vascular endothelial cells.
Materials and Methods
Cell culture and RNA extraction: Human umbilical vein endothelial cells (HUVEC) were isolated by collagenase digestion from normal umbilical cords. Cells were used at passage 2 to 4.
Tac/man/Realtime
PCR: For quantitative measurement of mRNA, 2 mg of total RNA was treated with DNase I for 15 min and subsequently used for cDNA synthesis. The reverse transcription was performed using a SuperScript pre-amplification system (Gibco BRL) with random oligonucleotide primers. TaqMan probes and primers for GTPCH and eNOS were designed using Primer Express (Applied Biosystems) and synthesized by Applied Biosystems.
Assay of biopterin:
Biopterin (BH 4 and more oxidized species) was measured essentially as described by Fukushima and Nixon (13) .
Nuclear run-on assay:
Isolation of nuclei and in vitro transcription proceeded. Linearized plasmids containing target cDNAs dissolved in 0.4 M NaOH were immobilized onto Hybond-N+ nylon membranes (Amersham Pharmacia) and hybridized with the labeled RNA. Blots were exposed to an imaging plate (Fuji Photo Film Co.) and signal intensity was quantified using a FUJIX bioimaging analyzer (BAS2000II).
Measurement of NO Synthesis:
Citrulline synthesis was measured by modification of a previously described technique (14) . Agonistinduced ['HJcitrulline production was calculated from the difference in radioactivity observed among ionomycin-stimulated cells and unstimulated cells. This was expressed as femtomoles/mg of cell protein.
St at is tic al A nalys is :
Data are presented as the mean ± SEM. Multiple comparisons were evaluated by ANOVA followed by Fisher's protected least significant difference test. A value of Ρ <0.05 was considered statistically significant.
Results
We first examined the mRNA levels of GTPCH and eNOS quantitatively using Real-time PCR in HUVEC treated with cerivastatin. As shown in Fig.lA . cerivastatin increased GTPCH mRNA at 6 h, after which it increased further and remained elevated for at least 24 h. Treatment of the cells with different concentrations of cerivastatin significantly increased GTPCH mRNA levels to between 0.01 and 1 μΜ (Fig. 1 ) . As shown in Fig. 1 , an increase in eNOS mRNA with cerivastatin was also observed at 6 h, after which the level of eNOS mRNA continued to increase and remained elevated for at least 24 h. Treatment of the cells with different concentrations of cerivastatin significantly increased eNOS mRNA levels to between 0.01 and 1 μΜ (Fig.  1 ) . In another experiment, we examined the effect of another statin, fluvastatin, on GTPCH and eNOS
Figure 1 (A) Effect of cerivastatin on GTPCH and eNOS mRNA levels in HUVEC. Cells were incubated with cerivastatin (0.01 -1 μΜ) for 24 h, after which mRNAs for GTPCH and eNOS were measured by Realtime PCR. Insert: Time course of mRNA levels following incubation with cerivastatin (0.5 μΜ). Data represent the mean ± SEM (n=3). *P <0.05 and **P <0.01 compared with control.
mRNA levels. Fluvastatin also increased the mRNA levels of both GTPCH and eNOS (data not shown). We next determined whether cerivastatin might increase cellular biopterin levels. Treatment of the cells with cerivastatin increased cellular biopterin levels in a concentration-dependent manner (Fig. 2) . The BH, content ot the cells was significantly higher than that of controls, while cellular 7,8-dihydrobiopterin (BH : ) levels were similar (data not shown).
We then examined whether or not an increased stability of mRNA could explain alterations in GTPCH induction by cerivastatin. Figure 3A shows that the rate of decay of GTPCH mRNA was not altered by incubating cells with cerivastatin. A half-life approximating 1.5 h was observed. We also evaluated eNOS mRNA stability under conditions where cells were incubated with cerivastatin. eNOS mRNA levels decreased with time in control cells and were not altered by treatment with cerivastatin (Fig. 4A) . We further examined whether or not the increased tran- Transcription of the isolated nuclei was analyzed by hybridizing ,2 P-labeled RNA to GTPCH and GAPDH cDNAs immobilized on nylon membranes. Representative of three experiments performed with similar results (top). Signals of GTPCH were quantified and normalized to those of GAPDH using a bioimaging analyzer (bottom). Data represent means of triplicate determinations (±SEM). **P <0.01 compared with control. scription of GTPCH mRNA could serve as the basis for the altered GTPCH mRNA induction by the statin. The transcription rate of the GTPCH gene assessed by nuclear run-on assay was substantially increased 6 h after exposure to cerivastatin (Fig. 3B) . The effect of GTPCH inhibition on cerivastatinmediated increases in BII4 levels and cNOS activity was assessed. The selective GTPCH inhibitor, 2,4-diamino-6-hydroxypyrimidine (DAHP), inhibits de novo synthesis of BH4 by acting as an analogue of the first pyrimidine intermediate formed in the GTPCH reaction (15) . Accordingly, preincubation of the cells with DAHP ( 1 mM, 24 h) caused a decrease in intracellular BH4 in control cells. Cerivastatin enhanced the BH4 levels, which were also attenuated with treatment with DAHP to the same levels as in the control cells with DAHP. In the presence of cerivastatin, ionomycin-stimulated citrulline formation was enhanced.
The potentiating effect of cerivastatin on citrulline formation was substantially attenuated by DAHP, in so much as the cellular availability of BH 4 had fallen, under these conditions (data not shown).
Discussion
Beneficial effects of acute and chronic BH 4 supplementation on endothelial function have been reported in animals and humans (8) (9) (10) (11) (12) . Furthermore, it appears that the beneficial effects of some antioxidants (e.g., vitamin C) on vascular function might be mediated by increases in intracellular BH 4 (14, 16) . The present study demonstrates that statins increase cellular biopterin by inducing GTPCH gene expression. This appears to cnhance NO formation and to reduce uncoupling of NOS leading to NOS-mediated oxygen reduction and formation of superoxide anions, along with hydrogen peroxide. Statins may increase eNOS activity by inducing eNOS, as well as by increasing the amount of available BH 4 . Uprcgulation of GTPCH mRNA by statins appears to result from transcriptional activation, while eNOS mRNA levels appear to increase due to stabilization of eNOS mRNA.
In addition to augmenting eNOS expression, cerivastatin and fluvastatin were observed to potentiate GTPCH gene expression and BH 4 synthesis of GTPCH in vascular endothelial cells. Thus, statins increase NO production and prevent relative shortages of BH 4 . This may shift the balance toward NOS-eatalyzed generation of protective NO and away from the production of deleterious reactive oxygen species.
